Recombinant human leukemia inhibitory factor does not improve implantation and pregnancy outcomes after assisted reproductive techniques in women with recurrent unexplained implantation failure.
In this randomized, double-blind, placebo-controlled, multicenter study, women (n = 149) with a history of at least two unexplained implantation failures after assisted reproductive techniques received recombinant human leukemia inhibitory factor, 150 microg SC twice daily for 7 days, or placebo. The clinical pregnancy rate after ET was significantly lower in patients receiving recombinant human leukemia inhibitory factor than in those receiving placebo (17.6% vs. 34.0%, respectively).
Brinsden
Peter R
PR
Bourn Hall Clinic, Bourn, Cambridge, Cambridgeshire, United Kingdom. peter@brinsden.net
Alam
Veronica
V
de Moustier
Beatrice
B
Engrand
Patrick
P
D000328:Adult; D004311:Double-Blind Method; D004624:Embryo Transfer / Q000379:methods; D047108:Embryonic Development / Q000187:drug effects*; D023381:Endpoint Determination; D005260:Female; D006801:Humans; D007247:Infertility, Female / Q000628:therapy*; D053605:Leukemia Inhibitory Factor / Q000494:pharmacology*; D011247:Pregnancy; D011256:Pregnancy Outcome; D018873:Pregnancy Rate; D011994:Recombinant Proteins / Q000494:pharmacology*; D027724:Reproductive Techniques, Assisted; D017211:Treatment Failure; D016896:Treatment Outcome
C507837:LIF protein, human; D053605:Leukemia Inhibitory Factor; D011994:Recombinant Proteins